Claims for Patent: 10,191,058

Summary for Patent: 10,191,058

Title:	Diagnosis of cancer by detecting auto-antibodies against vascular endothelial growth factor receptor (VEGFR)
Abstract:	The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor receptor (VEGFR) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor.
Inventor(s):	Heidecke; Harald (Berlin, DE), Schulze-Forster; Kai (Teltow, DE)
Assignee:	CELLTREND GMBH (Luckenwalde, DE)
Application Number:	15/115,904
Patent Claims:	1. A method for treating a vascular endothelial growth factor receptor (VEGFR) or vascular endothelial growth factor (VEGF) associated cancer, comprising (i) determining the level of antibodies against VEGFR in a sample from a subject suspected of having such cancer, (ii) comparing the determined level in the sample to a control level of VEGFR antibodies derived from subjects without cancer; (iii) identifying a subject having a decreased level of said antibodies in the subject's sample as compared to the level of said antibodies in the control, and (iv) administering to the subject from step (iii) a drug selected from the group consisting of an angiogenesis inhibitor, an anti-VEGF antibody, and bevacizumab. 2. The method according to claim 1, wherein the subject from step (iii) has a determined level of said antibodies of less than 0.9 fold as compared to the level of said antibodies from subjects without cancer. 3. The method according to claim 1, wherein the anti-VEGFR antibody is detected in an immunoassay. 4. The method according to claim 3, wherein the immunoassay is selected from the group of immunoprecipitation, enzyme immunoassay (EIA), radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), fluorescent immunoassay, a chemiluminescent assay, an agglutination assay, nephelometric assay, turbidimetric assay, a Western Blot, a competitive immunoassay, a noncompetitive immunoassay, a homogeneous immunoassay a heterogeneous immunoassay, a bioassay and a reporter assay such as a luciferase assay. 5. The method according to claim 1, wherein the sample is plasma or serum. 6. The method according to claim 1, comprising (a) contacting the sample with vascular endothelial growth factor receptor (VEGFR) or an antigenic peptide fragment thereof under conditions allowing for the formation of a complex between anti-VEGFR antibodies with VEGFR or a peptide fragment thereof, (b) detecting the complex. 7. The method of claim 6, wherein the VEGFR or the peptide fragment thereof is immobilized on a surface. 8. The method according to claim 6, wherein the complex is detected using a secondary antibody against the Fc portion of the anti-VEGFR antibody. 9. The method according to claim 8, wherein the anti-VEGFR antibody is an IgG-antibody and the secondary antibody is an anti-IgG antibody. 10. The method according to claim 9, wherein the secondary antibody is labeled with a detectable marker. 11. The method of claim 1, wherein the presence of one or more further markers for cancer is detected in the sample. 12. A method for treating progression or relapse of a vascular endothelial growth factor receptor (VEGFR) or vascular endothelial growth factor (VEGF) associated cancer in a subject, the method comprising (i) determining the level of antibodies against VEGFR in a sample from said subject, (ii) comparing the determined level in the sample to either one or both of a first and second VEGFR antibody control level, wherein a) the first VEGFR antibody control level is derived from subjects not showing relapse of cancer or mortality after treatment with said drug, and b) the second VEGFR antibody control level is derived from subjects showing relapse of cancer or mortality after treatment with said drug, and (iii) identifying a subject having a decreased level of said antibodies in the subject's sample as compared to the level of said antibodies in the first VEGFR antibody control and/or having an equal level of said antibodies as compared to the level of said antibodies in the second VEGFR control, and (iv) administering to said subject from step (iii) with a drug selected from the group consisting of an angiogenesis inhibitor, an anti-VEGF antibody, and bevacizumab. 13. A method for differential diagnosis and treatment of ovarian cancer comprising (i) determining the level of antibodies against vascular endothelial growth factor receptor (VEGFR) in a sample from a subject, (ii) comparing the determined level in the sample to either one or both of a first and second VEGFR antibody control level, a) wherein the first VEGFR antibody control level is derived from subjects suffering from ovarian cancer classified as Grade II or Grade III ovarian cancer, and b) wherein the second VEGFR antibody control level is derived from a subject suffering from ovarian cancer classified as Grade I ovarian cancer, (iii) identifying a subject having: an increased level of said antibodies in the sample from the subject as compared to the first VEGFR antibody control level; and/or an equal level of said antibodies in the sample from the subject as compared to the second VEGFR antibody control level as having Grade I ovarian cancer, (iv) identifying a subject having: a decreased level of said antibodies in the sample from the subject as compared to the second VEGFR antibody control level; and/or an equal level of said antibodies in the sample from the subject as compared to the first VEGFR antibody control level as having Grade II or Grade III ovarian cancer, and (v) administering to the subject from step (iii) or step (iv) a drug selected from the group consisting of an angiogenesis inhibitor, an anti-VEGF antibody, and bevacizumab. 14. The method for differential diagnosis of ovarian cancer according to claim 13, wherein a level of antibodies against VEGFR in the sample from the subject to be diagnosed of less than 0.9 fold as compared to the second VEGFR antibody control level is indicative for Grade II or Grade III ovarian cancer in said subject to be diagnosed, and/or wherein a level of antibodies against VEGFR in the sample from the subject to be diagnosed of more than 1.1 fold as compared to the first VEGFR antibody control level is indicative for Grade I ovarian cancer in said subject to be diagnosed.

Details for Patent 10,191,058

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2034-02-04